If you have been reading about synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
=== Legal status === Eflornithine, sold under the brand name Vaniqa, was granted marketing approval by the US FDA, the European Commission among others, is a topical prescription treatment that slows the growth of facial hair. Ornidyl, the injectable form of eflornithine hydrochloride, is licensed by Sanofi-Aventis, and is discontinued in the US. In July 2025, Norgine B.V. withdrew its application in the European Union for a marketing authorization of Ifinwil for the treatment of people with high-risk neuroblastoma (cancer of nerve cells in different parts of the body).
=== 1989 === January 4: Gulf of Sidra incident between America and Libya, similar to the 1981 Gulf of Sidra incident. January 7: Emperor Hirohito dies, marking the end of the Showa era in Japan. January 11: Communist Hungary introduces political reforms. January 19: The trade union Solidarity is legalized by the Polish government. January 20: George H. W. Bush is inaugurated as 41st President of the United States. February 2: Soviet troops withdraw from Afghanistan. February 3: Alfredo Stroessner was deposed in a coup led by Andrés Rodríguez. February 14: The Contra war effectively ends with the Tesoro Beach Accords happening in El Salvador with Costa Rica, El Salvador, Guatemala, Honduras and Nicaragua participating. An agreement is made that all contra forces are to disband in return for a free election to be held in February 1990. Although a few groups initially reject the agreement they eventually decide to participate. February 15: The Afghan Civil War begins after Soviet troops withdrawing from Afghanistan. February 19–21: Jakarta Informal Meeting II was held in Jakarta. This meeting succeeded in finding two important issues, namely the withdrawal of Vietnamese troops from Cambodia and the prevention of the return of the Pol Pot regime in Cambodia. Later, efforts to resolve the conflict will continue in International Conference in Paris on July 30–31, 1989. March 26: The Soviet Union holds the first round of legislative elections to the Congress of People's Deputies. June 3: Ayatollah Khomeini dies.
In 1974, Detroit elected its first black mayor, Coleman Young. Coleman Young aimed to create a racially diverse cabinet and police force, half black and half white members, leading to a new face representing Detroit on the global stage. Most important, however, was the population decline's negative effect on Detroit's economy. Following the population decline, Detroit's tax revenue significantly decreased. The government was receiving less revenue from taxpayers residing in the city which led to more foreclosures and overall unemployment, eventually culminating in the bankruptcy of 2013. Detroit's population continues to decline today, impacting its majority poor, black demographic the hardest. Because urban renewal, highway construction, and discriminatory loan policies contributed to white flight to the suburbs, the remaining poor, black city population endured radical disinvestment and a lack of public services such as dilapidated schools, a lack of safety, blighted properties, and waste, contributing the reality of families living in the city today. Furthermore, Detroit has the highest property tax of any major U.S. city, making it difficult for many families to afford to live there. White flight does appear to be reversing starting in the 1990s, with affluent white families returning to the city and gentrifying areas of urban decay and blight. However, this has caused many physical and cultural displacement issues, disproportionately impacting marginalized minority communities.
Sources: en.wikipedia.org
=== Depression === Levodopa has been reported to be inconsistently effective as an antidepressant in the treatment of depressive disorders. However, it was found to enhance psychomotor activation in people with depression.
Hence, even though nihonium is in group 13, it has several properties similar to the group 17 elements. (Tennessine in group 17 has some group-13-like properties, as it has three valence electrons outside the 7s2 7p2 closed shell.) Nihonium is expected to be able to gain an electron to attain this closed-shell configuration, forming the −1 oxidation state like the halogens (fluorine, chlorine, bromine, iodine, and astatine). This state should be more stable than it is for thallium as the SO splitting of the 7p subshell is greater than that for the 6p subshell. Nihonium should be the most electronegative of the metallic group 13 elements, even more electronegative than tennessine, the period 7 congener of the halogens: in the compound NhTs, the negative charge is expected to be on the nihonium atom rather than the tennessine atom. The −1 oxidation should be more stable for nihonium than for tennessine. The electron affinity of nihonium is calculated to be around 0.68 eV, higher than thallium's at 0.4 eV; tennessine's is expected to be 1.8 eV, the lowest in its group. It is theoretically predicted that nihonium should have an enthalpy of sublimation around 150 kJ/mol and an enthalpy of adsorption on a gold surface around −159 kJ/mol.
=== Pre-release === Before being preempted by its bigger sister label TriStar, the film was intended for release by Ben Ami's Triumph Releasing. The release date was originally pegged for January 1991, or February after the film's partial reboot in July. The first full release date to be floated around was May 3, 1991. The original cut was given an NC-17 rating, in what was claimed to be a first for an action film. The producers immediately assured that they were committed to securing an R rating, and edits were made accordingly. Bosworth embarked on an eight-city tour to promote the film, which avoided Seattle. The Seahawks refused to field media inquiries about their former player in the run-up to Stone Cold's release. The film's premiere took place at Universal Studios on May 16, 1991. In keeping with the film's tone, invitations bore the mention "No suits allowed", and Wichard chartered 250 Harley Davidsons, allowing some of the approximately 800 guests to ride two-up to the venue. The boisterous Wichard publicly denigrated other action stars for their advancing age and Arnold Schwarzenegger for looking awkward in a publicity shot as a biker. Bosworth floated the idea of changing his name to Bozworth, an allusion to his football nickname "The Boz", before conceding that it was another of his manager's publicity stunts. Wichard also pushed for the title change from The Brotherhood to Stone Cold to better emphasize his client.
== External links == "Rusfertide ( Code - C162883 )". EVS Explore. "Rusfertide Acetate ( Code - C180660 )". EVS Explore. Clinical trial number NCT05210790 for "A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)" at ClinicalTrials.gov
Sources: en.wikipedia.org
Variants encoded by alternative exons were reported in human and mouse corin. A variant allele (T555I/Q568P) was found in African Americans with hypertension and cardiac hypertrophy. The amino acid substitutions impaired corin activity. An insertion variant in exon 1 alters the cytoplasmic tail. This variant appeared more frequently in hypertensive patients. CORIN mutations were found in patients with hypertension. In the cat family (Felidae), mutant alleles of the corin gene are responsible for "golden" or "metallic" fur, in particular the "sunshine" coloration (FIFé EMS Code "u") of the Siberian Forest Cat breed, but also in the British Shorthair and some other domestic cats (where EMS Code "y" is used to denote this coloration), as well as in golden tigers.
== Further reading == De Vito, D.; Weber, J.; Merbach, A. E. “Calculated Volume and Energy Profiles for Water Exchange on t2g 6 Rhodium(III) and Iridium(III) Hexaaquaions: Conclusive Evidence for an Ia Mechanism” Inorganic Chemistry, 2004, Volume 43, pages 858–863. doi:10.1021/ic035096n Zumdahl, Steven S. Chemical Principles, Fifth Edition. New York: Houghton Mifflin, 2005. 943–946, 957. OCLC 77760970 Harris, D., Bertolucci, M., Symmetry and Spectroscopy. 1989 New York, Dover Publications
== Early life and education == Springer was born in Fort Benning, Georgia, in 1948. His father was a family physician. Springer attended public high school in Sacramento, California. In 1966, he enrolled at Yale University. After his freshman year, he dropped out and served as a Volunteers in Service to America (VISTA) volunteer. He did community development on the Yomba Shoshone Reservation in Nevada, including getting a road paved so children did not have to live away from home to attend high school. He then enrolled at the University of California, Berkeley, majoring in biochemistry and graduating with a BA in 1971. He went on to pursue a PhD under Jack Strominger at Harvard University, completing it in 1976.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.